

Media Release

AsiaMedic Delivers Strong 22% Growth in Core Diagnostic Imaging Revenue in 1H2026

Singapore, 14 August 2026

SGX Catalist-listed **AsiaMedic Limited** (the "**Company**" and, together with its subsidiaries, the "**Group**") today announced its unaudited financial results for the six months ended 30 June 2026 ("**1H2026**").

The Group recorded revenue of S\$16.2 million in 1H2026. Compared with 1H2025, revenue declined marginally by 2%, primarily due to the absence of the School Health Screening Projects and the deconsolidation of the Group's medical aesthetic business following the disposal of its controlling interest in 2025. Despite these changes to the Group's revenue mix, the Group's core diagnostic imaging business continued to deliver strong growth.

Revenue from diagnostic imaging and radiology services increased 22% year-on-year to S\$13.0 million, accounting for more than 80% of Group revenue and reinforcing its position as the Group's core business.

Supported by the continued strength of its diagnostic imaging business and improved contributions from associates, the Group significantly narrowed its net loss from S\$0.6 million in 1H2025 to S\$40,000 in 1H2026.

Financial Highlights

- Diagnostic imaging revenue increased 22% to S\$13.0 million, contributing over 80% of Group revenue.
- Group net loss narrowed by 93% to S\$40,000, from S\$0.6 million in 1H2025.
- Group EBITDA improved 10% to S\$1.9 million, reflecting stronger operating performance.
- Share of results of associates improved 26%, driven by stronger performance from Positron Tracers Pte. Ltd. and contributions from AsiaMedic Astique the Aesthetic Clinic Pte. Ltd., following the Group's divestment of its controlling stake in 2025.
- Cash and cash equivalents stood at S\$3.5 million, with an additional S\$5.0 million in other financial assets.

Mr Arifin Kwek (郭致宾), Chief Executive Officer of AsiaMedic Limited, said:

"Our first half performance demonstrates the resilience of AsiaMedic's core diagnostic imaging business. Despite the absence of the School Health Screening Projects and changes to the Group's business portfolio following the medical aesthetic transaction completed last year, diagnostic imaging continued to grow strongly and remained our principal revenue contributor.

The continued growth of our diagnostic imaging business reflects the strength of our core healthcare platform and the continued demand for our diagnostic imaging services. Together with improved contributions from our associates, this provides a solid foundation as we continue to optimise our business portfolio and improve operational efficiency, supporting the Group's long-term development."

Looking ahead, AsiaMedic will continue to focus on expanding its diagnostic imaging and health screening businesses while maintaining prudent cost and capital management. The Group believes long-term demand for diagnostic imaging and preventive healthcare services in Singapore remains supported by an ageing population and increasing healthcare awareness.

With established imaging centres in Orchard and Novena, together with its integrated healthcare platform, the Group remains well positioned to capture future growth opportunities while delivering high-quality patient care.

– END –

**This media release should be read in conjunction with the financial statements
announced on SGXNet.**

About AsiaMedic Limited

AsiaMedic Limited together with its subsidiaries ("AsiaMedic" or the "Group") is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to prevent and detect early illnesses to achieve positive experiences and clinical outcomes for patients. AsiaMedic is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).

The Group is committed to helping clients through practical and personalised solutions delivered with the highest professional standards of service and expertise in a timely, safe and consistent manner.

With convenient locations at Orchard and Novena, AsiaMedic is a preferred one-stop centre for:

- Diagnostic imaging and radiology services
- Medical wellness and health screening services
- Primary healthcare services

For more information, please visit www.asiamedic.com.sg

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954.

For media and analysts' queries, please contact:

Ms. Syenny Yu: syenny@asiamedic.com.sg

(Chief Financial Officer)